365mc, a South Korean medical institution specializing in fat reduction treatments, and Raziel Therapeutics, a global clinical-stage biopharmaceutical company, have announced a strategic collaboration to jointly advance the clinical and commercial development of RZL-012 in South Korea. RZL-012 is an injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.

365mc is renowned for its patient-centered and comprehensive approach to fat management, offering an integrated continuum of services encompassing surgical procedures, dietary counseling, and behavioral therapy.

Raziel Therapeutics is developing RZL-012, a novel chemical entity (NCE) designed to selectively disrupt adipocyte membranes, thereby leading to a reduction in localized subcutaneous fat. This drug is intended for aesthetic applications, such as treating submental fat and non-surgical body contouring. Clinical trials have demonstrated that RZL-012 induces adipocyte cell death, resulting in a substantial and enduring reduction in fat volume at the injection site.

Through this collaboration, the two companies will jointly design and implement the Phase 3 clinical strategy for RZL-012 in South Korea. Leveraging its extensive clinical experience, regulatory expertise, brand-building capabilities, and market access, 365mc will play a critical role in positioning RZL-012 as a best-in-class solution in the Korean aesthetic medicine market.

In addition, the companies will explore the development of a next-generation body contouring protocol by combining RZL-012 with 365mc’s proprietary LAMS (Liposuction Assisted Modeling System) procedure. LAMS is an innovative surgical technique for focal fat reduction developed by 365mc and is expected to serve as a platform for global market expansion through an integrated treatment solution.

As part of this partnership, 365mc will also make a strategic investment in Raziel Therapeutics, further underscoring its commitment to advancing innovation in the field of non-surgical fat reduction.

This partnership represents a convergence of 365mc’s leadership in obesity and aesthetic medicine with Raziel Therapeutics’ cutting-edge fat reduction technology. Together, the companies aim to set a new global standard in non-invasive body contouring.